TransMedics Group, Inc. (TMDX) TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Sector: Electromedical & Electrotherapeutic Apparatus
Industry: Medical - Devices
TransMedics Group, Inc. NASDAQ:TMDX Healthcare · Medical - Devices
Mkt Cap $2.29B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics granted inducement equity awards to nine new employees on October 28, 2026, consisting of options on 71,815 shares and 47,924 RSUs under its Inducement Plan.
CFO Fernando Araujo received the largest component: options on 34,419 shares and 22,969 RSUs. Options carry a $66.90 exercise price, equal to the October 28 close, with standard four-year vesting.
This is a routine Nasdaq Listing Rule 5635(c)(4) disclosure with no earnings, strategic, or operational content.
• 2d ago AI analysis › Press Release
TransMedics to Present at Upcoming Investor Conferences
TransMedics announced it will participate in three upcoming healthcare investor conferences.
Management is scheduled for fireside chats at the Stifel 2026 Healthcare Conference on November 10, the Jefferies Global Healthcare Conference in London on November 17, and the Piper Sandler 38th Annual Healthcare Conference on December 1.
Live and archived webcasts will be available on the company's investor relations website. The release contains no financial or operational updates.
• 3d ago AI analysis › Press Release
TransMedics selects Gogo Galileo HDX for nationwide organ transport fleet
globenewswire.com • 5d ago Press Release
TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026
TransMedics Group will report Q3 2026 financial results after market close on Thursday, November 5, 2026.
Management will host a conference call at 4:30 p.m. ET, with a live and archived webcast on the company's investor relations site.
This is a scheduling notice only — no results or guidance were included.
• 10d ago AI analysis › Press Release ⚠ 3
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
TransMedics appointed Fernando Araujo as Chief Financial Officer, effective September 21, 2026, succeeding Gerardo Hernandez, who moves to a new role as Commercial Strategic Advisor, LATAM.
Araujo brings more than 20 years of public-company finance leadership, most recently as CFO of GE HealthCare's $16 billion Advanced Imaging Solutions segment, with prior senior finance roles at 3M and General Electric.
Concurrent with the appointment, TransMedics reiterated its full-year 2026 revenue guidance of $737 million to $757 million, representing approximately 22% to 25% year-over-year growth. The outlook excludes any contribution from the recent strategic investment in PAD Aviation Service GmbH and will be revisited with third quarter 2026 results.
Management will participate in fireside chats at the Morgan Stanley and Baird healthcare conferences in New York on September 14 and 15, 2026.
• 1mo ago AI analysis › Press Release
TransMedics to Present at Upcoming September Investor Conferences
TransMedics management will participate in fireside chats at the Morgan Stanley 24th Annual Global Healthcare Conference on Sept. 14 and the Baird 2026 Global Healthcare Conference on Sept. 15.
Both events will take place in New York; webcasts will be available via the company's investor relations website.
No new financial or operational information was disclosed in this scheduling notice.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
TransMedics Reports Second Quarter 2026 Financial Results
TransMedics delivered record second-quarter revenue of $189.9 million, up 21% year-over-year, driven by higher utilization of the Organ Care System and growth in logistics services.
Despite the top-line strength, net income fell 55% to $14.7 million, or $0.41 per share, as operating expenses rose 49% to support clinical programs and infrastructure investments.
Management raised the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million, reflecting continued demand and the strategic investment in PAD Aviation.
• 2mo ago AI analysis › Press Release
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics granted inducement awards to 9 new employees on July 29, 2026, consisting of an aggregate of 18,762 stock options and 12,414 restricted stock units.
The stock options were granted with an exercise price of $78.00 per share, which was the closing price on the grant date, and vest over a four-year period beginning on the first anniversary of employment.
These awards were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) and the company's inducement plan.
• 2mo ago AI analysis › Press Release
TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
TransMedics Group announced its management team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026.
The presentation is scheduled to begin at 2:00 p.m. ET, with a live and archived webcast available on the company's investor relations website.
• 3mo ago AI analysis › Press Release
TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
TransMedics announced it will release its second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026.
The company's management team will host a conference call to discuss the results at 4:30 p.m. ET on the same day.
A live and archived webcast will be available on the Investors section of the TransMedics website.
• 3mo ago AI analysis › Press Release
TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
TransMedics completed a strategic investment in PAD Aviation, a Germany-based private aviation operator, to build a dedicated organ transplant logistics network across Europe.
The investment aims to replicate TransMedics' U.S. NOP model in Europe, utilizing PAD Aviation's fleet of nine aircraft and 24/7 hub to support transplant activities.
CEO Waleed Hassanein emphasized the partnership's potential to increase donor organ utilization and save more patients in the region.
• 3mo ago AI analysis › Press Release
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics granted 37,367 stock options and 24,848 restricted stock units to 14 new employees as inducements to join the company.
The grants were approved by the Compensation Committee and comply with NASDAQ Listing Rule 5635(c)(4).
Matthew S. Forsyth, the new Senior Vice President and General Counsel, received 23,171 options and 15,409 RSUs as part of these awards.
• 5mo ago AI analysis › Press Release
TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
prnewswire.com • 5mo ago Press Release ● Major ⚠ 2
TransMedics Reports First Quarter 2026 Financial Results
TransMedics reported Q1 2026 revenue of $173.9 million, up 21% year-over-year, driven by increased utilization of its Organ Care System and growth in logistics services.
Despite the revenue growth, operating margins contracted to 7.6% from 19.1% in the prior year due to higher investments in R&D and expansion costs, resulting in GAAP EPS of $0.20 compared to $0.70 last year.
The company reiterated its full-year 2026 revenue guidance of $727 million to $757 million, representing 20% to 25% growth, and announced a definitive agreement to invest in PAD Aviation to build a European transplant logistics network.
• 5mo ago AI analysis › Press Release ⚠ 2
TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
TransMedics entered a definitive agreement to invest in Germany-based PAD Aviation to establish a dedicated organ transplant air and ground logistics network in Europe.
This strategic move aims to replicate the company's successful U.S. NOP model, expanding access to its OCS perfusion platform and increasing transplant volumes across the EU.
The transaction is expected to close later in 2026 subject to regulatory approvals, though financial terms were not disclosed.
• 6mo ago AI analysis › Press Release
TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting
TransMedics unveiled the Controlled Hypothermic Organ Preservation System (CHOPS) at the ISHLT 2026 Annual Meeting to support its clinical programs and expand its product portfolio.
CHOPS is an active cooling device designed to facilitate control arm enrollment in the OCS ENHANCE Heart Part B and OCS DENOVO Lung trials by providing a stable alternative to static cold storage.
The company intends to submit an IDE amendment to the FDA to designate CHOPS as the control device for these trials, with regulatory review expected in the coming months.
• 6mo ago AI analysis › Press Release
TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026
TransMedics scheduled the release of its first quarter 2026 financial results for after the market close on Tuesday, May 5, 2026.
The management team will host a conference call at 4:30 p.m. ET to discuss the results.
A live and archived webcast will be accessible on the Investors section of the company's website.
• 6mo ago AI analysis › 
